Zoetis Inc (ZTS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zoetis Inc (ZTS) has a cash flow conversion efficiency ratio of 0.174x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($938.00 Million) by net assets ($5.40 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ZTS equity to assets ratio to measure how much of total assets are equity-financed.
Zoetis Inc - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Zoetis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Zoetis Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Zoetis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zoetis Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Pacific Insurance Group Co Ltd
SHG:601601
|
0.216x |
|
Fiserv, Inc.
NYSE:FI
|
0.072x |
|
ANSYS Inc
NASDAQ:ANSS
|
0.065x |
|
JSW Steel Limited
NSE:JSWSTEEL
|
0.114x |
|
Chunghwa Telecom Co Ltd
NYSE:CHT
|
0.080x |
|
Martin Marietta Materials Inc
NYSE:MLM
|
0.020x |
|
Arch Capital Group Ltd.
NASDAQ:ACGL
|
0.049x |
|
Heidelberg Materials AG
XETRA:HEI
|
0.169x |
Annual Cash Flow Conversion Efficiency for Zoetis Inc (2010–2024)
The table below shows the annual cash flow conversion efficiency of Zoetis Inc from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Zoetis Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.77 Billion | $2.95 Billion | 0.619x | +31.31% |
| 2023-12-31 | $4.99 Billion | $2.35 Billion | 0.471x | +8.57% |
| 2022-12-31 | $4.40 Billion | $1.91 Billion | 0.434x | -10.83% |
| 2021-12-31 | $4.54 Billion | $2.21 Billion | 0.487x | -13.57% |
| 2020-12-31 | $3.77 Billion | $2.13 Billion | 0.563x | -14.99% |
| 2019-12-31 | $2.71 Billion | $1.79 Billion | 0.663x | -19.09% |
| 2018-12-31 | $2.19 Billion | $1.79 Billion | 0.819x | +8.70% |
| 2017-12-31 | $1.79 Billion | $1.35 Billion | 0.754x | +58.44% |
| 2016-12-31 | $1.50 Billion | $713.00 Million | 0.476x | -21.85% |
| 2015-12-31 | $1.09 Billion | $664.00 Million | 0.609x | +29.99% |
| 2014-12-31 | $1.34 Billion | $626.00 Million | 0.468x | -33.86% |
| 2013-12-31 | $962.00 Million | $681.00 Million | 0.708x | +530.09% |
| 2012-12-31 | $4.04 Billion | $454.00 Million | 0.112x | -15.55% |
| 2011-12-31 | $3.74 Billion | $497.00 Million | 0.133x | +75.14% |
| 2010-12-31 | $3.34 Billion | $254.00 Million | 0.076x | -- |
About Zoetis Inc
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and… Read more